Protalix BioTherapeutics (PLX) Short term Debt (2016 - 2024)
Protalix BioTherapeutics' quarterly Short term Debt came in at $20.4 million in Q2 2024, little changed quarter-over-quarter from $20.4 million in Q1 2024.
Protalix BioTherapeutics has reported Short term Debt for 7 years, with the latest figure at $20.4 million in Q2 2024.
- For the quarter ending Q2 2024, Short term Debt changed N/A year-over-year to $20.4 million; the trailing twelve-month figure through Jun 2024 stood at $20.4 million (changed N/A YoY), and the FY2023 full-year result was $20.3 million, changed N/A from the prior year.
- Short term Debt for Q2 2024 stood at $20.4 million, roughly flat from $20.4 million in the prior quarter.
- The five-year high for Short term Debt was $56.4 million in Q2 2021, with the low at $3.2 million in Q3 2021.
- Average Short term Debt over 4 years is $31.3 million, with a median of $20.4 million recorded in 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 20.42 Mn |
| Mar 31, 2024 | 20.42 Mn |
| Dec 31, 2023 | 20.25 Mn |
| Sep 30, 2023 | 20.19 Mn |
| Sep 30, 2021 | 3.24 Mn |
| Jun 30, 2021 | 56.36 Mn |
| Mar 31, 2021 | 55.37 Mn |
| Dec 31, 2020 | 54.43 Mn |
| Mar 31, 2018 | 5.93 Mn |
| Dec 31, 2017 | 5.92 Mn |
| Sep 30, 2017 | 5.91 Mn |
| Dec 31, 2016 | 53.87 Mn |